^
Association details:
| Biomarker: | ERCC1 negative |
|---|---|
| Cancer: | Esophageal Adenocarcinoma |
| Regimen: | SOX (oxaliplatin + Teysuno (gimeracil/oteracil/tegafur)) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX
Published date:
02/17/2021
Excerpt:
Forty patients were enrolled and 48% completed all adjuvant cycles. Median dose intensity was 98% for S-1 and 62% for oxaliplatin….Patients with ERCC1 negative tumor expression had significantly better survival compared to ERCC1 positivity (p = 0.01).
DOI:
10.3390/cancers13040839
